Ενδιαφέρουσες επιχειρηματικές εξελίξεις επιφύλασσε η περασμένη χρονιά στον τομέα των εμβολίων, με την GlaxoSmithKline να «προσπερνά» τη Merck & Co ή MSD, όπως είναι ο διακριτικός τίτλος της εταιρίας στις … Continue Reading Οι κορυφαίες εταιρίες εμβολίων διεθνώς
The old saying “a rising tide lifts all boats,” famously borrowed in 1963 by President John F. Kennedy, certainly applied last year to the total compensation of biopharma CEOs, as surging … Continue Reading What the Top 10 Biopharma CEOs Are Making
Διατήρησε τις εκτιμήσεις της για τις πωλήσεις του έτους η Merck KGaA, καθώς οι πωλήσεις β΄ τριμήνου ενισχύθηκαν ελαφρώς, παρά το ότι επιβραδύνθηκε ο ρυθμός τους από τις νομισματικές μεταβολές. … Continue Reading Αύξηση πωλήσεων και μείωση κερδών για την Merck KGaA στο β΄ τρίμηνο
Την έντονη ανησυχία τους εκφράζουν οι αξιωματούχοι του Παγκόσμιου Οργανισμού Υγείας (ΠΟΥ) το στέλεχος του Έμπολα, ο οποίος έχει στοιχίσει τη ζωή σε 20 ανθρώπους, δεν έχει ακόμη ταυτοποιηθεί. Ανώτερος αξιωματούχος … Continue Reading Πιθανόν να μην υπάρχει εμβόλιο για νέα επιδημία του ιού Έμπολα
Dive Brief: Against a backdrop of intense market competition, Novo Nordisk has rolled out a direct-to-consumer campaign for Ozempic, its once-weekly, injectable Type 2 diabetes medication. Set to the tune … Continue Reading With diabetes competitive as ever, Novo launches Ozempic DTC campaign
For a while, IDO inhibitors were believed to be the hot new area for cancer drugs. Then in April, Merck & Co. and Incyte had a catastrophic failure with a combination trial of Merck’s Keytruda and … Continue Reading With Future on the Line, NewLink Genetics Restructures and Refocuses on IDO Inhibitors
Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer Bristol-Myers Squibb Company and Tsinghua University have entered into a collaboration to discover … Continue Reading Top Pharma News of the Week
As AbbVie Inc. continues to report Humira growth and investors continue to worry about biosimilar competition, the Chicago-area pharma offered a surprise when it presented its second quarter earnings: a better-than-expected performance for … Continue Reading AbbVie HCV Revenue Surprises Again, But Falloff Is Coming
In the field of immuno-oncology, the two dominant players are Merck & Company, with Keytruda and Bristol-Myers Squibb Company with Opdivo. PD-1 and PD-L1 are proteins found on cancer cells that allow them … Continue Reading Merck Takes Lead from Bristol-Myers Squibb for PD-1/PD-L1
AstraZeneca’s second-quarter report had a mix of good news and bad news. On the good news side, oncology sales rocketed 37 percent, with strong sales of Lynparza, Tagrisso and Imfinzi. On … Continue Reading AstraZeneca’s Cancer Drugs Mostly Soar With One Bomb Amidst Quarterly Report
Merck’s Keytruda may just be on its way to earlier use in head and neck cancer, an area where it once faced some questions. On Wednesday, the New Jersey drugmaker said that … Continue Reading Merck’s Keytruda shores up head and neck case with first-line trial win
So far in 2018, it’s been a good year for biotech initial public offerings (IPOs). According to a Crunchbase News article, in the second quarter of this year alone, there were at … Continue Reading A Deep Dive into This Year’s Biotech IPOs
Roche joined a growing list of Big Pharma companies calling a halt to drug price increases—or cutting them—after President Donald Trump’s naming and shaming. But that was after the … Continue Reading Roche halts price hikes for 2018—but only after it already raised them twice
Bristol-Myers Squibb is locked in some pretty big marketing battles—but it’ll have to soldier on without its commercial leader. On Monday, the New Jersey drugmaker said EVP and chief commercial officer … Continue Reading Bristol-Myers Squibb commercial chief Gordon jumps ship ahead of key Opdivo launch
Glancing at the headlines, it might seem like drug companies have a hard time avoiding anger over the prices of medications. But public opinions about them have changed in … Continue Reading RANKED: These are the most and least reputable drug companies in the world
Drug companies have been hit hard this year. Public opinion, trust and reputation of pharmaceutical companies appear to be eroding, according to a new analysis from the research consulting … Continue Reading These are the most — and least — reputable drug companies in the US
